Page 40 - Risk Evaluation News Today

As those in the reproductive health space scramble to keep up with the ever-changing landscape of mifepristone (Mifeprex) access, it seems that every party must have their say. ...

Reproductive health care and mifepristone Mifeprex access. Updates from DOJ, USPS, five letters signed by 40 state attorneys general, announcements from CVS and Walgreens, tweet by CA Governor Newsom, and movement in Texas case challenging FDA approval of mifepristone.

AMARILLO, Texas -- A federal judge in Texas raised questions Wednesday about a Christian groups effort to overturn federal regulators decades-old approval of a leading abortion drug, in a case that could threaten the countrys most common method for ending pregnancies.

The first hearing in a lawsuit that seeks to overturn F.D.A. approval of the pills takes place Wednesday morning in Texas.

The judge said he would decide soon whether to issue a preliminary injunction ordering the F.D.A. to withdraw its approval of the drug or wait for the full trial.

Life News

A federal judge in Texas soon could make one of the two pills used in medication abortions harder to come by, even in blue states that support abortion rights. Officials

U.S. Court of Appeals for Federal Circuit in Jazz Pharmaceuticals v. Avadel CNS Pharmaceuticals affirmed decision from Delaware court directing Jazz Pharmaceuticals to delist U.S. Patent No. 8,731,963 from FDA Approved Drug Products with Therapeutic Equivalence Evaluations.

Two US Drug Enforcement Administration proposals on how telehealth can be used going forward to prescribe controlled substances are drawing criticism from mental health and addiction treatment specialists.

On February 24, 2023, the U.S. Court of Appeals for the Federal Circuit, in Jazz Pharmaceuticals, Inc., v. Avadel CNS Pharmaceuticals, LLC, Case No. 23-1186, affirmed a decision from...